AIM:To evaluate the safety and efficacy of human embryonic stem cells(h ESCs)for the management of type 2 diabetes mellitus(T2DM).METHODS:Patients with a previous history of diabetes and its associated complications w...AIM:To evaluate the safety and efficacy of human embryonic stem cells(h ESCs)for the management of type 2 diabetes mellitus(T2DM).METHODS:Patients with a previous history of diabetes and its associated complications were enrolled and injected with hE SC lines as per the defined protocol.The patients were assessed using Nutech functional score(NFS),a numeric scoring scale to evaluate the patients for 11 diagnostic parameters.Patients were evaluated at baseline and at the end of treatment period 1(T1).All the parameters were graded on the NFS scale from 1to 5.Highest possible grade(HPG)of 5 was considered as the grade of best improvement.RESULTS:Overall,94.8%of the patients showed improvement by at least one grade of NFS at the end of T1.For all the 11 parameters evaluated,54%of patients achieved HPG after treatment.The four essential parameters(improvement in glycated hemoglobin(HbA 1c)and insulin level,and fall in number of other oral hypoglycemic drugs with and without insulin)are presented in detail.For Hb A1c,72.6%of patients at the end of T1 met the World Health Organization cut off value,i.e.,6.5%of HbA 1c.For insulin level,65.9%of patients at the end of T1 were able to achieve HPG.After treatment,the improvement was seen in 16.3%of patients who required no more than two medications along with insulin.Similarly,21.5%of patients were improved as their dosage regimen for using oral drugs was reduced to 1-2 from 5.CONCLUSION:hE SC therapy is beneficial in patients with diabetes and helps in reducing their dependence on insulin and other medicines.展开更多
目的:探讨游离甲状腺素(FT4)、促甲状腺激素(TSH)及糖化血红蛋白(HbA1c)、胰岛素样生长因子-1(IGF-1)在评估重组人生长激素(Recombinant Human Growth Hormone,rhGH)长期治疗矮小症患儿中的临床价值。方法:选取2018年12月至2020年1月于...目的:探讨游离甲状腺素(FT4)、促甲状腺激素(TSH)及糖化血红蛋白(HbA1c)、胰岛素样生长因子-1(IGF-1)在评估重组人生长激素(Recombinant Human Growth Hormone,rhGH)长期治疗矮小症患儿中的临床价值。方法:选取2018年12月至2020年1月于我院进行治疗的43例矮小症患儿作为观察组,给予rhGH治疗;再选取50例同时期于我院进行健康体检儿童作为对照组。检测并比较两组研究对象游离三碘甲状腺原氨酸(FT3)、FT4和TSH、HbA1c、IGF-1的水平;比较观察组治疗前、治疗3、6、12、24个月后生长发育情况(身高、体质量、骨龄、生长速度),HbA1c、IGF-1和胰岛素样生长因子结合蛋白-3(IGFBP3)水平,甲状腺功能指标(FT3、FT4、TSH),骨代谢和骨吸收指标[碱性磷酸酶(AKP)、胶原羧基末端肽同分异构体(CTX)、骨钙素(OC)]水平。结果:两组研究对象FT3、FT4、TSH、HbA1c水平比较差异无统计学意义(P>0.05);观察组IGF-1水平低于对照组(P<0.05)。与治疗前相比,观察组治疗3、6、12、24个月后身高、体质量、骨龄生长速率均更高(P<0.05),不同时间身高、体质量、骨龄和生长速率组间比较差异有统计学意义(P<0.05),且均呈增长趋势;HbA1c水平比较差异无统计学意义(P>0.05),不同时间组间比较差异无统计学意义(P>0.05);IGF-1、IGFBP3水平均更高(P<0.05),不同时间组间比较差异有统计学意义(P<0.05);FT3、FT4和TSH水平比较差异无统计学意义(P>0.05),不同时间FT3、FT4和TSH水平组间比较差异无统计学意义(P>0.05);AKP、CTX和OC水平明显升高(P<0.05),不同时间AKP、CTX和OC水平组间比较差异具有统计学意义(P<0.05)。结论:应用rhGH长期治疗矮小症患儿对患儿甲状腺功能、糖代谢功能无明显不良影响,患儿生长发育情况明显改善,可以通过持续检测IGF-1、IGFBP3及骨代谢和吸收水平了解治疗效果。展开更多
文摘AIM:To evaluate the safety and efficacy of human embryonic stem cells(h ESCs)for the management of type 2 diabetes mellitus(T2DM).METHODS:Patients with a previous history of diabetes and its associated complications were enrolled and injected with hE SC lines as per the defined protocol.The patients were assessed using Nutech functional score(NFS),a numeric scoring scale to evaluate the patients for 11 diagnostic parameters.Patients were evaluated at baseline and at the end of treatment period 1(T1).All the parameters were graded on the NFS scale from 1to 5.Highest possible grade(HPG)of 5 was considered as the grade of best improvement.RESULTS:Overall,94.8%of the patients showed improvement by at least one grade of NFS at the end of T1.For all the 11 parameters evaluated,54%of patients achieved HPG after treatment.The four essential parameters(improvement in glycated hemoglobin(HbA 1c)and insulin level,and fall in number of other oral hypoglycemic drugs with and without insulin)are presented in detail.For Hb A1c,72.6%of patients at the end of T1 met the World Health Organization cut off value,i.e.,6.5%of HbA 1c.For insulin level,65.9%of patients at the end of T1 were able to achieve HPG.After treatment,the improvement was seen in 16.3%of patients who required no more than two medications along with insulin.Similarly,21.5%of patients were improved as their dosage regimen for using oral drugs was reduced to 1-2 from 5.CONCLUSION:hE SC therapy is beneficial in patients with diabetes and helps in reducing their dependence on insulin and other medicines.
文摘目的:探讨游离甲状腺素(FT4)、促甲状腺激素(TSH)及糖化血红蛋白(HbA1c)、胰岛素样生长因子-1(IGF-1)在评估重组人生长激素(Recombinant Human Growth Hormone,rhGH)长期治疗矮小症患儿中的临床价值。方法:选取2018年12月至2020年1月于我院进行治疗的43例矮小症患儿作为观察组,给予rhGH治疗;再选取50例同时期于我院进行健康体检儿童作为对照组。检测并比较两组研究对象游离三碘甲状腺原氨酸(FT3)、FT4和TSH、HbA1c、IGF-1的水平;比较观察组治疗前、治疗3、6、12、24个月后生长发育情况(身高、体质量、骨龄、生长速度),HbA1c、IGF-1和胰岛素样生长因子结合蛋白-3(IGFBP3)水平,甲状腺功能指标(FT3、FT4、TSH),骨代谢和骨吸收指标[碱性磷酸酶(AKP)、胶原羧基末端肽同分异构体(CTX)、骨钙素(OC)]水平。结果:两组研究对象FT3、FT4、TSH、HbA1c水平比较差异无统计学意义(P>0.05);观察组IGF-1水平低于对照组(P<0.05)。与治疗前相比,观察组治疗3、6、12、24个月后身高、体质量、骨龄生长速率均更高(P<0.05),不同时间身高、体质量、骨龄和生长速率组间比较差异有统计学意义(P<0.05),且均呈增长趋势;HbA1c水平比较差异无统计学意义(P>0.05),不同时间组间比较差异无统计学意义(P>0.05);IGF-1、IGFBP3水平均更高(P<0.05),不同时间组间比较差异有统计学意义(P<0.05);FT3、FT4和TSH水平比较差异无统计学意义(P>0.05),不同时间FT3、FT4和TSH水平组间比较差异无统计学意义(P>0.05);AKP、CTX和OC水平明显升高(P<0.05),不同时间AKP、CTX和OC水平组间比较差异具有统计学意义(P<0.05)。结论:应用rhGH长期治疗矮小症患儿对患儿甲状腺功能、糖代谢功能无明显不良影响,患儿生长发育情况明显改善,可以通过持续检测IGF-1、IGFBP3及骨代谢和吸收水平了解治疗效果。
